Using albumin to improve the therapeutic properties of diabetes treatments

Diabetes, Obesity and Metabolism

Volumn 14, Issue 2, 2012, Pages 121-129

  Ahren B ^a   Burke, B ^b  

^a LUND UNIVERSITY   (Sweden)

^b MEDITECH MEDIA LTD   (United Kingdom)

Author keywords

Albiglutide; Albulin; Albumin; Exenatide; Glucagon like peptide 1; Insulin detemir; Liraglutide; Review

Indexed keywords

ALBIGLUTIDE; ALBUMIN; DRUG CARRIER; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN DERIVATIVE; LIRAGLUTIDE; PLASMA PROTEIN; TASPOGLUTIDE;

ACYLATION; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; CRYSTAL STRUCTURE; DETOXIFICATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LIPID METABOLISM; METAL BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC PRESSURE; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 84855356092     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01482.x     Document Type: Review

References (89)

1. International Diabetes Federation. The global burden: epidemiology and morbidity. 2010. Available from URL: Accessed 16 December 2010.
2. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
3. Ahren B. GLP-1 for type 2 diabetes. Exp Cell Res 2011; 317: 1239-1245.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
5. Fasano M, Curry S, Terreno E et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005; 57: 787-796.
6. Peters T Jr. All About Albumin. San Diego, CA: Academic Press, 1995.
7. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975; 11: 824-832.
8. Bhattacharya AA, Grune T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000; 303: 721-732.
9. Gomez-Perez FJ, Rull JA. Insulin therapy: current alternatives. Arch Med Res 2005; 36: 258-272.
10. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132: 171-183.
11. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312(Pt 3): 725-731.
12. Ballou GA, Boyer PD, Luck JM, Lum FG. The heat coagulation of human serum albumin. J Biol Chem 1944; 153: 589-605.
13. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16(Suppl. 5): 6-11.
14. Sen S, Jalan R, Williams R. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003; 35: 1306-1311.
15. Christodoulou J, Sadler PJ, Tucker A. A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy. Eur J Biochem 1994; 225: 363-368.
16. Espósito BP, Najjar R. Interactions of antitumoral platinum-group metallodrugs with albumin. Coord Chem Rev 2002; 232: 137-149.
17. Keaney JF Jr, Simon DI, Stamler JS et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993; 91: 1582-1589.
18. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002; 25: 695-704.
19. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004; 32: 755-759.
20. Giroux EL, Henkin RI. Macromolecular ligands of exchangeable copper, zinc and cadmium in human serum. Bioinorg Chem 1973; 2: 125-133.
21. Foote JW, Delves HT. Albumin bound and alpha 2-macroglobulin bound zinc concentrations in the sera of healthy adults. J Clin Pathol 1984; 37: 1050-1054.
22. Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA. Albumin as a zinc carrier: properties of its high-affinity zinc-binding site. Biochem Soc Trans 2008; 36(Pt 6): 1317-1321.
23. Tarushi A, Raptopoulou CP, Psycharis V, Terzis A, Psomas G, Kessissoglou DP. Zinc(II) complexes of the second-generation quinolone antibacterial drug enrofloxacin: structure and DNA or albumin interaction. Bioorg Med Chem 2010; 18: 2678-2685.
24. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008; 582: 1783-1787.
25. Bar-Or D, Rael LT, Lau EP et al. An analog of the human albumin N-terminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. Biochem Biophys Res Commun 2001; 284: 856-862.
26. Halliwell B. Albumin-an important extracellular antioxidant? Biochem Pharmacol 1988; 37: 569-571.
27. Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M. Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 2001; 18: 632-639.
28. Sakurai Y, Ma SF, Watanabe H et al. Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates. Pharm Res 2004; 21: 285-292.
29. Drabkin DL. Heme binding and transport-a spectrophotometric study of plasma glycoglobulin hemochromogens. Proc Natl Acad Sci U S A 1971; 68: 609-613.
30. Jalan R, Schnurr K, Mookerjee RP et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-564.
31. Kreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080-1085.
32. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994; 269: 16712-16719.
33. Hassanein TI, Tofteng F, Brown RS Jr et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862.
34. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19: 569-577.
35. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals 2006; 34: 55-59.
36. Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7: 2288-2297.
37. Wunder A, Muller-Ladner U, Stelzer EH et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170: 4793-4801.
38. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-19.
39. Zeuzem S, Yoshida EM, Benhamou Y et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 407-417.
40. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419.
41. Balan V, Nelson DR, Sulkowski MS et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 35-45.
42. Osborn BL, Olsen HS, Nardelli B et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-548.
43. Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000; 43: 1253-1256.
44. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.
45. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-1867.
46. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038-1044.
47. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
48. Woodward A, Weston P, Casson IF, Gill GV. Nocturnal hypoglycaemia in type 1 diabetes-frequency and predictive factors. QJM 2009; 102: 603-607.
49. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.
50. Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279-285.
51. Miyashita Y, Nishimura R, Nemoto M et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008; 7: 16.
52. Novo Nordisk. Insulin detemir (Levemir) Package Insert. Princeton, NJ: Novo Nordisk, 2007.
53. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998; 19: 608-624.
54. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
55. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
56. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
57. Hallschmid M, Jauch-Chara K, Korn O et al. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 2010; 59: 1101-1107.
58. Nishimura E, Sorensen AR, Hansen BF et al. Insulin degludec is a new-generation ultra-long-acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential (Abstract 1406-p). Diabetes 2010; 59(Suppl. 1): A375.
59. Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
60. ConjuChem Biotechnologies. About DAC™. Available from URL: Accessed 15 December 2010.
61. Duttaroy A, Kanakaraj P, Osborn BL et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005; 54: 251-258.
62. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
63. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
64. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-E988.
65. Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276(5 Pt 2): R1541-R1544.
66. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004; 36: 804-810.
67. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
68. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
69. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
70. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
71. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286.
72. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
73. Ahren B. Exenatide: a nover treatment of type 2 diabetes. Therapy 2005; 2: 207-222.
74. Exenatide (Byetta) Prescribing Information. Available from URL: Accessed 25 February 2011.
75. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
76. Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-1261.
77. Raskin P, Mora PF. Glycaemic control with liraglutide: the phase 3 trial programme. Int J Clin Pract Suppl 2010; 64: 21-27.
78. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
79. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-1921.
80. Meece J. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy 2009; 29(12 Pt 2): 33S-42S.
81. Sebokova E, Christ AD, Wang H et al. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010; 151: 2474-2482.
82. Dong JZ, Shen Y, Zhang J, Tsomaia N, Mierke DF, Taylor JE. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes Obes Metab 2011; 13: 19-25.
83. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009; 32: 1237-1243.
84. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: 1880-1886.
85. Matthews JE, Stewart MW, De Boever EH et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-4817.
86. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008; 134: 1137-1147.
87. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ. An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407.
88. Kim I, Kim TH, Ma K et al. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 2010; 21: 1513-1519.
89. Novo Nordisk. Liraglutide (Victoza) Package Insert. Princeton, NJ: Novo Nordisk, 2010.